vs

Side-by-side financial comparison of Health In Tech, Inc. (HIT) and Silence Therapeutics plc (SLN). Click either name above to swap in a different company.

Silence Therapeutics plc is the larger business by last-quarter revenue ($15.7M vs $9.1M, roughly 1.7× Health In Tech, Inc.). Health In Tech, Inc. runs the higher net margin — -4.0% vs -14.7%, a 10.7% gap on every dollar of revenue.

Tetra Tech, Inc. is an American consulting and engineering services firm based in Pasadena, California. The company provides consulting, engineering, program management, and construction management services in the areas of water, environment, infrastructure, resource management, energy, and international development.

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

HIT vs SLN — Head-to-Head

Bigger by revenue
SLN
SLN
1.7× larger
SLN
$15.7M
$9.1M
HIT
Higher net margin
HIT
HIT
10.7% more per $
HIT
-4.0%
-14.7%
SLN

Income Statement — Q4 FY2025 vs Q1 FY2024

Metric
HIT
HIT
SLN
SLN
Revenue
$9.1M
$15.7M
Net Profit
$-302.6K
$-2.3M
Gross Margin
45.3%
82.2%
Operating Margin
-5.9%
-35.6%
Net Margin
-4.0%
-14.7%
Revenue YoY
Net Profit YoY
EPS (diluted)
$-0.01
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HIT
HIT
SLN
SLN
Q4 25
$9.1M
Q3 25
$9.9M
Q2 25
$9.6M
Q1 25
$8.9M
Q1 24
$15.7M
Net Profit
HIT
HIT
SLN
SLN
Q4 25
$-302.6K
Q3 25
$452.2K
Q2 25
$630.6K
Q1 25
$498.6K
Q1 24
$-2.3M
Gross Margin
HIT
HIT
SLN
SLN
Q4 25
45.3%
Q3 25
51.8%
Q2 25
65.9%
Q1 25
59.9%
Q1 24
82.2%
Operating Margin
HIT
HIT
SLN
SLN
Q4 25
-5.9%
Q3 25
6.0%
Q2 25
8.7%
Q1 25
7.7%
Q1 24
-35.6%
Net Margin
HIT
HIT
SLN
SLN
Q4 25
-4.0%
Q3 25
4.6%
Q2 25
6.6%
Q1 25
5.6%
Q1 24
-14.7%
EPS (diluted)
HIT
HIT
SLN
SLN
Q4 25
$-0.01
Q3 25
$0.01
Q2 25
$0.01
Q1 25
$0.01
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HIT
HIT
SLN
SLN
Cash + ST InvestmentsLiquidity on hand
$7.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$17.1M
$156.8M
Total Assets
$23.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HIT
HIT
SLN
SLN
Q4 25
$7.7M
Q3 25
$8.0M
Q2 25
$8.1M
Q1 25
$7.6M
Q1 24
Stockholders' Equity
HIT
HIT
SLN
SLN
Q4 25
$17.1M
Q3 25
$17.2M
Q2 25
$16.4M
Q1 25
$14.2M
Q1 24
$156.8M
Total Assets
HIT
HIT
SLN
SLN
Q4 25
$23.1M
Q3 25
$22.8M
Q2 25
$22.2M
Q1 25
$21.3M
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HIT
HIT
SLN
SLN
Operating Cash FlowLast quarter
$3.1M
$-9.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HIT
HIT
SLN
SLN
Q4 25
$3.1M
Q3 25
$674.0K
Q2 25
$1.5M
Q1 25
$527.4K
Q1 24
$-9.1M
Capex Intensity
HIT
HIT
SLN
SLN
Q4 25
Q3 25
Q2 25
Q1 25
Q1 24
0.0%
Cash Conversion
HIT
HIT
SLN
SLN
Q4 25
Q3 25
1.49×
Q2 25
2.35×
Q1 25
1.06×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HIT
HIT

Revenues From Fees$6.5M71%
Other$1.6M18%
Revenues From Underwriting Modeling ICE$1.0M11%

SLN
SLN

Segment breakdown not available.

Related Comparisons